V
Vittorio Bellotti
Researcher at University College London
Publications - 159
Citations - 9792
Vittorio Bellotti is an academic researcher from University College London. The author has contributed to research in topics: Amyloidosis & Amyloid. The author has an hindex of 46, co-authored 152 publications receiving 8968 citations. Previous affiliations of Vittorio Bellotti include University of Pavia & Hammersmith Hospital.
Papers
More filters
Journal ArticleDOI
Molecular mechanisms of amyloidosis.
TL;DR: The molecular basis of various types of amyloidosis is reviewed and new ways of treating these disorders are proposed.
Journal ArticleDOI
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
David R. Booth,Margaret Sunde,Vittorio Bellotti,Vittorio Bellotti,Carol V. Robinson,Winston L. Hutchinson,Paul E. Fraser,Philip N. Hawkins,Christopher M. Dobson,Sheena E. Radford,Sheena E. Radford,Colin C.F. Blake,Mark B. Pepys +12 more
TL;DR: Biophysical studies suggest that partly folded intermediates are involved in fibrillogenesis, and this may be relevant to amyloidosis generally.
Journal ArticleDOI
Targeting C-reactive protein for the treatment of cardiovascular disease
Mark B. Pepys,Gideon M. Hirschfield,Glenys A. Tennent,J. Ruth Gallimore,Melvyn C. Kahan,Vittorio Bellotti,Vittorio Bellotti,Philip N. Hawkins,Rebecca M. Myers,Martin D. Smith,Alessandra Polara,Alexander J. A. Cobb,Alexander J. A. Cobb,Steven V. Ley,J. Andrew Aquilina,J. Andrew Aquilina,Carol V. Robinson,Isam Sharif,Gillian A. Gray,Caroline A. Sabin,Michelle C. Jenvey,Simon Kolstoe,D Thompson,D Thompson,Stephen P Wood +24 more
TL;DR: Therapeutic inhibition of CRP is a promising new approach to cardioprotection in acute myocardial infarction and may also provide neuroprotection in stroke and potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production.
Journal ArticleDOI
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Karl Bodin,Stephan Ellmerich,Melvyn C. Kahan,Glenys A. Tennent,Andrzej Loesch,Janet A. Gilbertson,Winston L. Hutchinson,Palma Mangione,Palma Mangione,J. Ruth Gallimore,David J. Millar,Shane Minogue,Amar P. Dhillon,Graham W. Taylor,Arthur R. Bradwell,Aviva Petrie,Julian D. Gillmore,Vittorio Bellotti,Vittorio Bellotti,Marina Botto,Philip N. Hawkins,Mark B. Pepys +21 more
TL;DR: It is shown that administration of anti-human-SAP antibodies to mice with amyloid deposits containing human SAP triggers a potent, complement-dependent, macrophage-derived giant cell reaction that swiftly removes massive visceral amyloids deposits without adverse effects.
Journal ArticleDOI
Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation.
Giampiero Esposito,R. Michelutti,Giuliana Verdone,Paolo Viglino,Helena Hernández,Carol V. Robinson,Angela Amoresano,F. Dal Piaz,Maria Chiara Monti,Piero Pucci,Palma Mangione,Monica Stoppini,Giampaolo Merlini,Giuseppina Ferri,Vittorio Bellotti +14 more
TL;DR: Limited proteolysis experiments and analysis by mass spectrometry support the conformational modifications identified by NMR and suggest that δN6β2‐m could be a key intermediate of a proteolytic pathway of β2‐microglobulin.